Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Preferred Shares (2023 - 2026)

Lucid Diagnostics filings provide 3 years of Preferred Shares readings, the most recent being $54.3 million for Q4 2025.

  • On a quarterly basis, Preferred Shares changed 0.27% to $54.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $54.3 million, a 0.27% change, with the full-year FY2025 number at $54.3 million, changed 0.27% from a year prior.
  • Preferred Shares hit $54.3 million in Q4 2025 for Lucid Diagnostics, roughly flat from $54.3 million in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $55.9 million in Q2 2024 to a low of $13.6 million in Q1 2023.
  • Median Preferred Shares over the past 3 years was $54.3 million (2025), compared with a mean of $40.6 million.
  • Biggest five-year swings in Preferred Shares: surged 310.41% in 2024 and later decreased 2.94% in 2025.
  • Lucid Diagnostics' Preferred Shares stood at $18.6 million in 2023, then soared by 192.18% to $54.4 million in 2024, then dropped by 0.27% to $54.3 million in 2025.
  • The last three reported values for Preferred Shares were $54.3 million (Q4 2025), $54.3 million (Q3 2025), and $54.4 million (Q2 2025) per Business Quant data.